Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
- Conditions
- ArthritisPainOsteoarthritis
- Interventions
- Biological: Placebo IVBiological: Tanezumab SCBiological: Tanezumab IVBiological: Placebo SC
- Registration Number
- NCT01089725
- Lead Sponsor
- Pfizer
- Brief Summary
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.
- Detailed Description
This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 385
- Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren- Lawrence score of greater than or equal to 2
- 18 years of age or greater
- Two methods of birth control one of which must be barrier if of childbearing potential
- Willing to discontinue pain medication except as permitted per protocol
- Pregnancy or wishing to be pregnant during the course of the study, lactating women
- Body Mass Index (BMI) greater than 39
- Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol.
- Previous exposure to a Nerve Growth Factor (NGF) antibody
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo IV - 2.5 mg tanezumab SC and placebo IV Placebo IV - Placebo Placebo SC - 2.5 mg tanezumab SC and placebo IV Tanezumab SC - 5 mg tanezumab SC and placebo IV Tanezumab SC - 10 mg tanezumab IV Placebo SC - 5 mg tanezumab SC and placebo IV Placebo IV - 10 mg tanezumab SC and placebo IV Placebo IV - 10 mg tanezumab IV Tanezumab IV - 10 mg tanezumab SC and placebo IV Tanezumab SC -
- Primary Outcome Measures
Name Time Method Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 Baseline, Week 16 The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16 Baseline, Week 16 The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.
Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis Score at Week 16 Baseline, Week 16 Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 1, 2, 4, 8, and 12 Baseline, Weeks 1, 2, 4, 8, and 12 The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.
Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score Weeks 1, 2, 4, 8, 12, and 16 The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 1, 2, 4, 8, and 12 Baseline, Weeks 1, 2, 4, 8, and 12 Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 1, 2, 4, 8, 12, and 16 Baseline, Weeks 1, 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific 24-item questionnaire, which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee. WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores. WOMAC pain, physical function and stiffness subscale and average score ranges from 0 to 10, where higher score indicates worse response.
Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 1, 2, 4, 8, 12, and 16 Baseline, Weeks 1, 2, 4, 8, 12, and 16 Participants answered: "How much pain have you had when walking on a flat surface?" Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain. Higher score indicated greater pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 1, 2, 4, 8, and 12 Baseline, Weeks 1, 2, 4, 8, and 12 The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Number of Participants With Improvement of at Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis Weeks 1, 2, 4, 8, 12, and 16 Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value.
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response Weeks 1, 2, 4, 8, 12, and 16 The OMERACT-OARSI responder index is based on 3 parameters. OMERACT-OARSI response: greater than or equal to (\>=) 50 percent (%) improvement from baseline and absolute change from baseline of \>=2 units at week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: \>=20% improvement from baseline and absolute change from baseline of \>=1 unit at week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score range: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score range: 0-10, higher score=higher pain/difficulty).
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 1, 2, 4, 8, 12, and 16 Baseline, Weeks 1, 2, 4, 8, 12, and 16 The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 2 individual questions scored on NRS of 0 to 10, with higher scores indicating more stiffness. Total score range for WOMAC stiffness subscale score is 0 to 10, where higher scores indicate more stiffness. Stiffness is defined as a sensation of decreased ease in movement of the knee.
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 16 Baseline, Week 16 SF-36v2 is a standardized self-administered survey evaluating 8 aspects/domains of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The total score for each domain is scaled 0-100 (100 = highest level of functioning).
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 16 Baseline, Week 16 SF-36v2: standardized self-administered survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100 (100=highest level of functioning). For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States \[US\] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score \[better functioning\])/lower (in case of negative z-score \[worse functioning\]) participant's value was relative to the mean of the reference population.
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Subscale Score at Weeks 1, 2, 4, 8, 12, and 16 Weeks 1, 2, 4, 8, 12, 16 The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a NRS of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 are reported.
Change From Baseline in Average Pain Score in the Index Knee at Weeks 1, 2, 4, 8, 12 and 16 Baseline, Weeks 1, 2, 4, 8, 12, and 16 Participants assessed average osteoarthritis pain in their knee in the past 24 hours on an 11-point NRS ranging from 0 (no pain) to 10 (worst pain). Higher score indicated greater pain. Baseline score was calculated as the mean of the scores over the 3 days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores within each study week.
Time to Discontinuation Due to Lack of Efficacy Baseline up to Week 24 Median time to discontinuation due to lack of efficacy for participants who discontinued due to lack of efficacy was reported.
Duration of Rescue Medication Use Weeks 1, 2, 4, 8, 12, and 16 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. Duration of rescue medication use is calculated as the number of study days per week when any rescue medication was taken.
Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 1, 2, 4, 8, 12, and 16 Baseline, Weeks 1, 2, 4, 8, 12, and 16 Participants answered: "How much pain have you had when going up or down stairs?" Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain. Higher score indicated greater pain.
Percentage of Participants Who Used Rescue Medication Weeks 1, 2, 4, 8, 12, and 16 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. Incidence of rescue medication use is calculated as any use of rescue medication during the study week in question.
Amount of Rescue Medication Taken Weeks 1, 2, 4, 8, 12, and 16 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. The amount of rescue medication taken is the total dose (in mg) of acetaminophen rescue medication over the study week in question.
Trial Locations
- Locations (87)
Clinical Pharmacology Study Group
🇺🇸Worcester, Massachusetts, United States
Arthritis Associates, PLLC
🇺🇸Hattiesburg, Mississippi, United States
Houston Institute for Clinical Research
🇺🇸Houston, Texas, United States
Valley Research
🇺🇸Fresno, California, United States
Benchmark Research
🇺🇸San Angelo, Texas, United States
Probe Clinical Research Corp.
🇺🇸Santa Ana, California, United States
Triwest Research Associates
🇺🇸La Mesa, California, United States
Advanced Clinical Research Institute
🇺🇸Anaheim, California, United States
Trinity Clinical Trials
🇺🇸Santa Ana, California, United States
Synergy Clinical Research Center
🇺🇸National City, California, United States
Jacksonville Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
West Coast Radiology Center
🇺🇸Anaheim, California, United States
Providence Clinical Research
🇺🇸Burbank, California, United States
Greensboro Imaging
🇺🇸Greensboro, North Carolina, United States
FMC Clinical Trials
🇺🇸Upland, California, United States
Wake Research Associates, LLC
🇺🇸Raleigh, North Carolina, United States
North Georgia Clinical Research
🇺🇸Woodstock, Georgia, United States
Andrew Porges, MD, PC
🇺🇸Roslyn, New York, United States
North Georgia Internal Medicine
🇺🇸Woodstock, Georgia, United States
Westside Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
BayCare Outpatient Imaging at Bardmoor
🇺🇸Largo, Florida, United States
Wichita Clinic PA
🇺🇸Wichita, Kansas, United States
Altoona Center for Clinical Research
🇺🇸Duncansville, Pennsylvania, United States
Apex Medical Research, AMR, Inc.
🇺🇸Chicago, Illinois, United States
LION Research
🇺🇸Norman, Oklahoma, United States
Community Research
🇺🇸Cincinnati, Ohio, United States
Pharmquest
🇺🇸Greensboro, North Carolina, United States
Grayline Clinical Drug Trials
🇺🇸Wichita Falls, Texas, United States
Advanced Clinical Research
🇺🇸West Jordan, Utah, United States
Westbury Medical Clinic
🇺🇸Houston, Texas, United States
G. Timothy Kelly, MD
🇺🇸Las Vegas, Nevada, United States
Sterling Research Group, Ltd.
🇺🇸Cincinnati, Ohio, United States
Colorado Hematology
🇺🇸Englewood, Colorado, United States
Colorado Orthopedic Consultants, P.C.
🇺🇸Englewood, Colorado, United States
Professional Research Network of Kansas, LLC
🇺🇸Wichita, Kansas, United States
Redpoint Research
🇺🇸Phoenix, Arizona, United States
Quality Clinical Research, Inc.
🇺🇸Omaha, Nebraska, United States
Vaughn H. Mancha, Jr., MD, PC
🇺🇸Montgomery, Alabama, United States
Allergy and Rheumatology Medical Clinic, Inc.
🇺🇸La Jolla, California, United States
Stamford Therapeutics Consortium
🇺🇸Stamford, Connecticut, United States
Innovative Research of West Florida, Inc.
🇺🇸Clearwater, Florida, United States
Fleming Island Center for Clinical Research
🇺🇸Fleming Island, Florida, United States
DMI Research, Inc.
🇺🇸Pinellas Park, Florida, United States
Bluegrass Community Research, Inc.
🇺🇸Lexington, Kentucky, United States
Physician Research Collaboration, LLC
🇺🇸Lincoln, Nebraska, United States
McBride Clinic
🇺🇸Norman, Oklahoma, United States
Health Research Institute
🇺🇸Oklahoma City, Oklahoma, United States
Lebanon Internal Medicine Associates
🇺🇸Lebanon, Pennsylvania, United States
Little York Medical Center
🇺🇸Houston, Texas, United States
Nature Coast Clinical Research
🇺🇸Crystal River, Florida, United States
St. Petersburg Arthritis Center
🇺🇸Saint Petersburg, Florida, United States
PMG Research of Charlotte
🇺🇸Charlotte, North Carolina, United States
Wake Internal Medicine Consultants, Inc.
🇺🇸Raleigh, North Carolina, United States
Founders Research Corporation
🇺🇸Philadelphia, Pennsylvania, United States
Clinical Research Center of Reading, LLP
🇺🇸Wyomissing, Pennsylvania, United States
Accurate Clinical Research Inc
🇺🇸Nassau Bay, Texas, United States
Mercury Clinical Research
🇺🇸Houston, Texas, United States
Clinical Trial Network
🇺🇸Houston, Texas, United States
Clinical Investigations of Texas, LLC
🇺🇸Plano, Texas, United States
Hypothe Test, LLC
🇺🇸Roanoke, Virginia, United States
Internist Associates of Texas
🇺🇸Kingwood, Texas, United States
Sonora Clinical Research
🇺🇸Boise, Idaho, United States
Asif Cochinwala, MD, P.A.
🇺🇸Houston, Texas, United States
Charlottesville Medical Research
🇺🇸Charlottesville, Virginia, United States
Beacon Clinical Research, LLC
🇺🇸Brockton, Massachusetts, United States
Pioneer Research Solutions, Inc
🇺🇸Sugar Land, Texas, United States
Sunshine Research Center
🇺🇸Opa-locka, Florida, United States
Accurate Clinical Research
🇺🇸Houston, Texas, United States
Sonoma Clinical Research, LLC.
🇺🇸Boise, Idaho, United States
Novara Clinical Research
🇺🇸Mesa, Arizona, United States
Office of Cynthia Morgan, MD
🇺🇸Washington, District of Columbia, United States
BenchMark Research
🇺🇸Metairie, Louisiana, United States
Arthritis Treatment Center
🇺🇸Frederick, Maryland, United States
The Center for Rheumatology and Bone Research
🇺🇸Wheaton, Maryland, United States
Troy Internal Medicine, PC
🇺🇸Troy, Michigan, United States
Mountain State Clinical Research
🇺🇸Clarksburg, West Virginia, United States
Billings Clinic Infusion Center
🇺🇸Billings, Montana, United States
Midwest Minor Medical
🇺🇸Omaha, Nebraska, United States
Health Concepts
🇺🇸Rapid City, South Dakota, United States
East-West Medical Research Institute
🇺🇸Honolulu, Hawaii, United States
Ann Arbor Clinical Reserch
🇺🇸Ann Arbor, Michigan, United States
FutureSearch Trials of Neurology
🇺🇸Austin, Texas, United States
Tekton Research, Inc
🇺🇸Austin, Texas, United States
Tekton Research, Inc.
🇺🇸Austin, Texas, United States
Billings Clinic Research Center
🇺🇸Billings, Montana, United States
Coastal Carolina Research Center
🇺🇸Mount Pleasant, South Carolina, United States
SoFHA Clinical Research
🇺🇸Johnson City, Tennessee, United States